Aymeric Couturier Shares Recent Studies on Anticoagulation and Atrial Fibrillation in Dialysis
Aymeric Couturier, Nephrologist at American Hospital;Necker Hospital, shared on LinkedIn:
”Anticoagulation and atrial fibrillation in dialysis: a paradigm shift on the horizon
Recent data show that the net benefit of oral anticoagulation remains uncertain in this high-risk population.
• An editorial by An S. De Vriese (JASN, 2025) calls for a reconsideration of our practices: caution with VKAs, possible use of appropriate DOACs, and openness to non-pharmacological strategies (atrial occlusion).
• The SAFE-D pilot trial (JASN, 2025) comparing warfarin, apixaban, and no anticoagulation in 151 dialysis patients with AF demonstrates the feasibility of a large-scale trial, but above all highlights the lack of clear benefit at this stage.
Three randomized trials already published — VALKYRIE (rivaroxaban vs. warfarin, n=132), RENAL-AF (apixaban vs. warfarin, n=154) and AXADIA-AFNET 8 (apixaban vs. warfarin, n=97)—show, despite their small sample sizes, a trend favoring DOACs over VKAs.
Three ongoing trials, this time with large sample sizes (718 to 1,500 patients), finally include a non-anticoagulation arm:
• DANWARD (warfarin vs. no anticoagulation, n=718)
• SACK (apixaban vs. no anticoagulation, n=1,400)
• VISIONAIRE (edoxaban vs. warfarin vs. no anticoagulation, n=1,500)
The time has come for an individualized approach, incorporating informed patient choice, therapeutic alternatives, and shared decision-making.”
Read the full article in JASN.
Article 1: Anticoagulation for Atrial Fibrillation in Kidney Failure. A Call to Arms
Authors: De Vriese, An S.
Read the full article in JASN.
Article 2: Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis. A Pilot Randomized Controlled Trial
Authors: Harel Ziv, Smyth Brendan, Badve Sunil V., Blum Daniel, Beaubien-Souligny William, Silver Samuel A., Clark Edward, Suri Rita, Mavrakanas Thomas A., Sasal Joanna, Prasad Bhanu, Eikelboom John, Tennankore Karthik, Rigatto Claudio, Prce Ivana, Madore Francois, Mac-Way Fabrice, Steele Andrew, Zeng Yangmin, Sholzberg Michelle, Dorian Paul, Yan Andrew T., Sood Manish M., Gladstone David J., Tseng Eric, Kitchlu Abhijat, Walsh Michael, Sapir Danny, Oliver Matthew J., Krishnan Murali, Kiaii Mercedeh, Wong Nikki, Kotwal Sradha, Battistella Marisa, Acedillo Rey, Lok Charmaine, Weir Matthew, Wald Ron
Stay updated on the latest scientific advances in the field of coagulation with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week